Sarepta Therapeutics Newsroom

Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating

Futu NewsOct 24 23:32

Baird Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsOct 24 23:32

Optimistic Buy Rating for Sarepta Therapeutics Amid Strong International Demand and Collaborative Potential

TipRanksOct 24 22:49

RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $182

Futu NewsOct 21 19:31

Sarepta Therapeutics Analyst Ratings

BenzingaOct 21 19:03

RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)

TipRanksOct 21 18:39

Jefferies Initiates Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $165

Futu NewsOct 21 17:33

BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $210

Futu NewsOct 18 17:33

Needham Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $205

Futu NewsOct 14 19:31

Barclays Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203

Futu NewsOct 11 19:31

Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsOct 11 19:31

Buy Rating on Sarepta Therapeutics: Promising Long-Term Data and Market Opportunity Amid Stock Weakness

TipRanksOct 11 19:22

Raymond James Upgrades Sarepta Therapeutics(SRPT.US) to Buy Rating, Announces Target Price $150

Futu NewsOct 10 21:35

Sarepta Therapeutics Price Target Announced at $150.00/Share by Raymond James

Dow JonesOct 10 21:12

Sarepta Therapeutics Analyst Ratings

BenzingaOct 10 21:03

BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsOct 10 20:33

Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200

Futu NewsOct 10 11:32

Buy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Launch and Solid Financial Outlook

TipRanksOct 10 11:07

RBC Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Raises Target Price to $182

Futu NewsOct 9 03:31

Sarepta Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesOct 4 23:32